Massé Fabienne, Hascoët Martine, Dailly Eric, Bourin Michel
EA 3256, Neurobiologie de l'anxiété et de la dépression, Faculté de Médecine, BP 53508, 1 rue Gaston Veil, 44035, Nantes cedex 01, France.
Psychopharmacology (Berl). 2006 Jan;183(4):471-81. doi: 10.1007/s00213-005-0220-3. Epub 2005 Nov 24.
Selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors demonstrated an anxiolytic-like effect in the four-plate test (FPT). (+/-)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI; a 5-HT2A receptor agonist) also possessed strong anxiolytic-like effect in the same test. A 5-HT2A mechanism seems to be implicated in the mechanism of action of both antidepressants and DOI in this test. On the other hand, the alpha-adrenergic ligands have also demonstrated an activity in other models of anxiety. A previous study demonstrated that the alpha2-adrenoceptor agonists abolished the anxiolytic-like effect of antidepressants.
The aim of the present study was to evaluate the role of noradrenergic system on the regulation of 5-HT2 receptors implicated in the DOI anxiolytic-like activity in the FPT.
First, the effect of noradrenergic and serotonergic lesions on DOI anxiolytic-like activity was studied in the FPT. Second, the effect of co-administration of alpha-adrenoceptor ligands and DOI was evaluated in the same test.
The noradrenergic and serotonergic lesions had no effect on DOI (1 mg/kg) anti-punishment activity in the FPT. Adrafinil 0.25 and 4 mg/kg (an alpha1-adrenoceptor agonist), prazosin 0.5 and 2 mg/kg (an alpha1-adrenoceptor antagonist) and idazoxan 1 and 4 mg/kg (an alpha2-adrenoceptor antagonist) did not modify the activity of DOI. Clonidine 0.06 mg/kg, guanabenz 0.125 and 0.5 mg/kg (two alpha2-adrenoceptor agonists) and guanfacine 0.06 and 0.125 mg/kg (a specific alpha2A-adrenoceptor agonist) completely abolished DOI-induced increase in punished passages.
These results indicate that the DOI seems to act on the 5-HT2 receptors post-synaptically located. The effect of DOI is regulated by the alpha2-adrenoceptors.
选择性5-羟色胺再摄取抑制剂以及5-羟色胺与去甲肾上腺素再摄取抑制剂在四板试验(FPT)中表现出抗焦虑样效应。(±)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI;一种5-HT2A受体激动剂)在同一试验中也具有较强的抗焦虑样效应。在该试验中,5-HT2A机制似乎与抗抑郁药和DOI的作用机制有关。另一方面,α-肾上腺素能配体在其他焦虑模型中也表现出活性。先前的一项研究表明,α2-肾上腺素能受体激动剂可消除抗抑郁药的抗焦虑样效应。
本研究旨在评估去甲肾上腺素能系统在调节参与FPT中DOI抗焦虑样活性的5-HT2受体方面的作用。
首先,在FPT中研究去甲肾上腺素能和5-羟色胺能损伤对DOI抗焦虑样活性的影响。其次,在同一试验中评估α-肾上腺素能受体配体与DOI联合给药的效果。
去甲肾上腺素能和5-羟色胺能损伤对FPT中DOI(1mg/kg)的抗惩罚活性没有影响。阿屈非尼0.25和4mg/kg(一种α1-肾上腺素能受体激动剂)、哌唑嗪0.5和2mg/kg(一种α1-肾上腺素能受体拮抗剂)以及咪唑克生1和4mg/kg(一种α2-肾上腺素能受体拮抗剂)均未改变DOI的活性。可乐定0.06mg/kg、胍那苄0.125和0.5mg/kg(两种α2-肾上腺素能受体激动剂)以及胍法辛0.06和0.125mg/kg(一种特异性α2A-肾上腺素能受体激动剂)完全消除了DOI诱导的受罚通道增加。
这些结果表明,DOI似乎作用于突触后定位的5-HT2受体。DOI的作用受α2-肾上腺素能受体调节。